Fecal microbiota transplantation as potential first-line treatment for patients with Clostridioides difficile infection and prior appendectomy

Jing-Wen Zhao,Bing Chang,Li-Xuan Sang

Jing-Wen Zhao,Li-Xuan Sang,Department of Gastroenterology,Shengjing Hospital of China Medical University,Shenyang 110022,Liaoning Province,China

Bing Chang,Department of Gastroenterology,The First Affiliated Hospital of China Medical University,Shenyang 110001,Liaoning Province,China

Abstract Clostridioides difficile infection (CDI) is a global health problem.The association of appendectomy on the severity and prognosis of CDI has been reported in many literatures,but there are still contradictions.In a retrospective study entitled “Patients with Closterium diffuse infection and prior appendectomy may be prone to word outcomes” published in World J Gastrointest Surg 2021,the author found that prior appendectomy affects the severity of CDI.Appendectomy may be a risk factor for increasing the severity of CDI.Therefore,it is necessary to seek alternative treatment for patients with prior appendectomy when they are more likely to have severe or fulminant CDI.

Key Words: Clostridioides difficile infection;Appendectomy;Fecal microbiota transplantation;Intestinal microbiota;Toxic megacolon;Colectomy

TO THE EDlTOR

We read with great interest the article by Shaikhet al[1] entitled patients with “Clostridium difficile infection and prior appendectomy may be prone to worse outcomes”.They studied the association of appendectomy on the severity and prognosis ofClostridioides difficileinfection (CDI).CDI remains a major health care problem globally.Due to super virulent strains and the abuse of antibiotics,the incidence and severity of CDI have been increasing since 2000[2].

We found that there were contradictions in the discussion of the role of prior appendectomy on CDI in the previous literature.The sample size of this article is much larger than that of previous studies,which is one of its strengths,thus providing more powerful evidence for future research on the relationship between prior appendectomy and CDI.This study did not prove that the risk of CDI recurrence in patients with prior appendectomy was increased.However,appendectomy affected the severity of CDI and was also related to toxic megacolon and colectomy,which was consistent with the conclusion of Yonget al[3],who stated that appendectomy may be a risk factor for the increase in CDI severity.The specific reason still needs to be determinedviaexperimental and clinical research.It is speculated that the appendix is the "safe house" of normal colon bacteria[4],and appendectomy may reduce intestinal immune reactivity,which may reduce intestinal resistance toClostridioides difficileand lead to a worse outcome of CDI.To further confirm and validate the results of this paper,a larger prospective study is needed.

It is necessary to seek a new treatment plan when patients with prior appendectomy are more likely to have severe or fulminant CDI.The fecal microbiota transplantation (FMT) is a method approved by most international guidelines for recurrent CDI[5,6].Although FMT has been proven to be safe and effective in recurrent infections,its efficacy in severe or fulminant CDI is still unclear.A series of studies show that FMT combined with antibiotics can reduce the mortality of severe and fulminant CDI[7] and reduces the occurrence of surgery[8].Early FMT can improve the survival rate of patients with severe CDI.Severe CDI patients without FMT have a serious prognosis and a very high mortality rate (30%-60%)[9].FMT treatment in primary severe CDI has a very low disease recurrence rate[10].Tixieret al[11] provided low-quality evidence to support FMT as a safe and effective treatment for adult severe and fulminant CDI.At present,some scholars believe that FMT can be used as the first-line treatment for severe and fulminant CDI[12],but more evidence is needed.

FMT should be performed by an experienced team after a thorough risk assessment.In clinical practice,the need for FMT or even multiple FMTs can be assessed by establishing a risk assessment system that includes prior appendectomy as a risk factor.Additionally,it has been demonstrated that the presence of pseudomembranous lesions under colonoscopy and highly pathogenic CDI strains are predictors of FMT failure,so patients with severe or fulminant CDI may require multiple FMTs until the pseudomembranous lesions disappear and clinical remission is achieved[13].We believe that early FMT is a better option to modify the composition of the patient's gut microbiota in a durable way,prophylactically reducing the incidence of toxic megacolon as well as colectomy.

Many risk factors for CDI are immutable (such as advanced age)[14].The current prevention strategies mainly focus on improving hand hygiene,contact isolation,environmental purification and antibiotic management plans[15].These strategies have been proven to be effective but still have limitations.Shaikh made us realize that new strategies are needed to prevent CDI when dealing with specific patients.Although probiotics are not included in the guidelines for the prevention and treatment of CDI,some probiotic such as strains from Saccharomyces,Bifidobacterium,or Lactobacillus genera have potential protective effect againstClostridioides difficile[16].For patients who have undergone prior appendectomy,preventive improvement of intestinal flora is the key to avoid worse outcomes.

Many studies have confirmed the long-term safety of FMT for recurrent CDI[17].A multicenter longterm follow-up study also showed that FMT is successful and safe for patients with severe or refractory CDI[18].These findings all emphasize the value of FMT in avoiding the repeated use of antibiotics which may cause dysbiosis of the intestinal microbial community permanently.FMT can restore the biological diversity of intestinal microbiota to restore the normal intestinal function.All these enlighten us that FMT has the potential to be the first-line treatment for patients with CDI and prior appendectomy.

FOOTNOTES

Author contributions:Zhao JW wrote the letter;Chang B and Sang LX supervised the manuscript drafting;All authors contributed important intellectual content during manuscript drafting and revision.

Conflict-of-interest statement:There are no conflicts of interest to report.

Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers.It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license,which permits others to distribute,remix,adapt,build upon this work non-commercially,and license their derivative works on different terms,provided the original work is properly cited and the use is noncommercial.See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin:China

ORClD number:Jing-Wen Zhao 0000-0002-1587-2501;Bing Chang 0000-0003-1965-5827;Li-Xuan Sang 0000-0002-4562-0022.

S-Editor:Zhang H

L-Editor:A

P-Editor:Zhang H